237 related articles for article (PubMed ID: 25758153)
1. Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics.
Halim AB
Ann N Y Acad Sci; 2015 Jun; 1346(1):63-70. PubMed ID: 25758153
[TBL] [Abstract][Full Text] [Related]
2. The biggest challenges currently facing companion diagnostic advancement.
Halim AB
Expert Rev Mol Diagn; 2014 Jan; 14(1):27-35. PubMed ID: 24308333
[TBL] [Abstract][Full Text] [Related]
3. Do companion diagnostics make economic sense for drug developers?
Agarwal A
N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
[TBL] [Abstract][Full Text] [Related]
4. Improving laboratory efficiencies through significant time reduction in the preanalytical phase.
Prusa R; Doupovcova J; Warunek D; Stankovic AK
Clin Chem Lab Med; 2010 Feb; 48(2):293-6. PubMed ID: 20001850
[No Abstract] [Full Text] [Related]
5. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
6. Challenges in the clinical implementation of precision medicine companion diagnostics.
Keeling P; Clark J; Finucane S
Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
[TBL] [Abstract][Full Text] [Related]
7. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
Love D; Stratton E; Stocum M
N Biotechnol; 2012 Sep; 29(6):689-94. PubMed ID: 22743138
[TBL] [Abstract][Full Text] [Related]
8. Overcoming regulatory and economic challenges facing pharmacogenomics.
Cohen JP
N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
[TBL] [Abstract][Full Text] [Related]
9. The Regulation of Companion Diagnostics: A Global Perspective.
Ansari M
Ther Innov Regul Sci; 2013 Jul; 47(4):405-415. PubMed ID: 30235516
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine: elusive dream or imminent reality?
Lesko LJ
Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
[TBL] [Abstract][Full Text] [Related]
11. Regulatory considerations for companion diagnostic devices.
Lee EY; Shen HC
Biomark Med; 2015; 9(1):67-75. PubMed ID: 25605456
[TBL] [Abstract][Full Text] [Related]
12. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
13. [PHARMACEUTICAL INDUSTRY AND PERSONALIZED MEDICINE: A PARADIGM SHIFT IN THE DEVELOPMENT OF NEW DRUGS].
Scheen AJ
Rev Med Liege; 2015; 70(5-6):237-41. PubMed ID: 26285445
[TBL] [Abstract][Full Text] [Related]
14. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
Front Genet; 2015; 6():357. PubMed ID: 26858745
[TBL] [Abstract][Full Text] [Related]
15. Protein array-based companion diagnostics in precision medicine.
Poulsen TBG; Karamehmedovic A; Aboo C; Jørgensen MM; Yu X; Fang X; Blackburn JM; Nielsen CH; Kragstrup TW; Stensballe A
Expert Rev Mol Diagn; 2020 Dec; 20(12):1183-1198. PubMed ID: 33315478
[TBL] [Abstract][Full Text] [Related]
16. Qualification versus validation of biomarkers.
Doust J
Scand J Clin Lab Invest Suppl; 2010; 242():40-3. PubMed ID: 20515275
[TBL] [Abstract][Full Text] [Related]
17. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
Cowling T; Boucher M
Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
[TBL] [Abstract][Full Text] [Related]
18. Preanalytical quality improvement: from dream to reality.
Lippi G; Chance JJ; Church S; Dazzi P; Fontana R; Giavarina D; Grankvist K; Huisman W; Kouri T; Palicka V; Plebani M; Puro V; Salvagno GL; Sandberg S; Sikaris K; Watson I; Stankovic AK; Simundic AM
Clin Chem Lab Med; 2011 Jul; 49(7):1113-26. PubMed ID: 21517699
[TBL] [Abstract][Full Text] [Related]
19. The impact of genetic biomarkers on drug and companion diagnostic return on investment.
Keeling P
Drug Discov Today; 2011 Oct; 16(19-20):850-1. PubMed ID: 21906694
[No Abstract] [Full Text] [Related]
20. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
Miossec P; Verweij CL; Klareskog L; Pitzalis C; Barton A; Lekkerkerker F; Reiter S; Laslop A; Breedveld F; Abadie E; Flamion B; Dere W; Mpofu S; Goel N; Ethgen D; Mitlak B; Ormarsdóttir S; Rao R; Tsouderos Y; Reginster JY;
Ann Rheum Dis; 2011 Oct; 70(10):1713-8. PubMed ID: 21784723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
